No country in the world can boast a 100% accurate blood screening program. According to the World Health Organization (WHO), the risk of infection with Hepatitis B, C and HIV from donor blood is less than .02% in developed countries, while this same risk can exceed 3.5% in developing countries.
Our patented method for assessing the viability of lymphotropic viruses offers a new tool for solving this problem.
Both of the leading methods, polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (EIA), have serious drawbacks. Both require the presence of a fairly large number of antibodies or viral particles in order to deliver a conclusive positive result. When concentrations are below the threshold of detection for EIA and PCR, the result can be a false negative (meaning that the virus is present in the blood but at a concentration below what traditional methods can identify). This leads to diagnostic errors, which are unacceptable in a blood screening program. The proposed method was developed over a decade by a team of academic and technical experts.
Both reliable and simple to use, the proposed method for assessing the viability of lymphotropic viruses is based on an innovative testing algorithm that delivers accurate results by detecting lymphotropic viruses at concentrations, or titers, lower than the threshold of detection for the PCR method.
Patents for the method have already been obtained from the European Patent Office (EPO), the United States Patent and Trademark Office (USPTO), the State of Israel Patent Office, the Companies and Intellectual Property Commission of the Republic of South Africa, the African Regional Intellectual Property Organization (ARIPO), and the Eurasian Patent Organization.
- The method requires no additional equipment purchases, since the equipment available in any diagnostic lab is sufficient;
- Likewise, there is no need for training or on-site consultations with the developers. PCR lab technicians can simply read the manual and apply the method;
- Target cells are readily available and inexpensive lymphocytes from healthy donor blood (no expensive cell cultures need to be purchased);
- The method detects the viability of Hepatitis B (HBV), C (HCV) and HIV even after long-term storage or processes that inactivate these viruses.